Screener
Biogen BIIB Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi.
The source filing: Biogen’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 6:36 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000875045-26-000075
| Line item | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|
| Share-based compensation | 161.4 | 155.9 |
| Contingent consideration | 23.0 | 22.8 |
| Deferred income taxes | (4.0) | (59.1) |
| (Gain) loss on strategic investments | (61.8) | 33.2 |
| Other | 64.0 | 16.0 |
| Changes in operating assets and liabilities, net of effects of business acquired: | ||
| Accounts receivable | (166.0) | (170.5) |
| Due from anti-CD20 therapeutic programs | 11.8 | 4.2 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Biogen's net gains (losses) on investments?
- Biogen (BIIB) reported net gains (losses) on investments of $42.8M in Q2 2026.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Biogen's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude